Please select the option that best describes you:

Is it appropriate to offer definitive trimodality therapy, as an equivalent option to neoadjuvant chemotherapy followed by radical cystectomy, in patients with muscle-invasive bladder cancer regardless of fitness or platinum eligibility?  

Has this recent retrospective analysis published in Lancet Oncology changed your practice?

Answer from: Radiation Oncologist at Academic Institution
Radiation Oncologist at Duke University Health System
Another relevant resource here is a paper we wrote...
Sign in or Register to read more